Data presented at Kidney Week 2025 showed single subcutaneous administration of megalin-STRIKERs resulted in increased excretion of disease-related solute levels lasting for at least 2 months Dr. Ravi ...

Single subcutaneous dose of ADX-038 achieved near-complete alternative pathway suppression for 6 months, supporting potent and selective CFB ...

GSK’s antibody-drug conjugate strategy may be making more headlines recently, but the British pharma hasn’t forgotten about ...

Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)King of Prussia, Pennsylvania ...

Findings provide scientific insights into the contribution of small interfering RNA (siRNA) and therapeutic vaccination towards the HBV functional cure strategy DURHAM, N.C. and BEIJING, Nov. 7, 2025 ...

RNA interference using small interfering RNAs (siRNAs) has become a mainstay of functional gene characterization and has ...

Argo Biopharmaceutical Co., Ltd. (Argo Biopharma), a clinical-stage small interfering RNA (siRNA) therapeutics company, today announced it will present Phase I data for BW-20805 at the American ...

RNA interference silences gene expression through short interfering 21–23-mer double-strand RNA segments that guide mRNA degradation in a sequence-specific fashion. Here we report that siRNAs inhibit ...

SLN (“Silence” or “the Company”), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported its financial results for the third quarter ended September ...

The current coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has challenged healthcare facilities globally. Even though the FDA ...

GSK now owns the global development and commercialisation rights to Empirico's COPD-targeting (siRNA) oligonucleotide, ...